Icure Pharmaceutical Incorporation (175250) - Cash Flow Conversion Efficiency

Latest as of March 2025: -0.055x

Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has a cash flow conversion efficiency ratio of -0.055x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.28 Billion ≈ $-2.23 Million USD) by net assets (₩59.43 Billion ≈ $40.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Icure Pharmaceutical Incorporation - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Icure Pharmaceutical Incorporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Icure Pharmaceutical Incorporation for a breakdown of total debt and financial obligations.

Icure Pharmaceutical Incorporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Space Com TA:SCC	0.037x
Electra Battery Materials Corp NASDAQ:ELBM	-0.046x
Copenhagen Capital A/S CO:CPHCAP-ST	0.015x
American Creek Resources Ltd V:AMK	-0.114x
iBio, Inc. Common Stock NASDAQ:IBIO	-0.093x
Electra Battery Materials Corp V:ELBM	-0.046x
Nahar Industrial Enterprises Limited NSE:NAHARINDUS	0.143x
Wisekey International Holding AG NASDAQ:WKEY	-0.128x

Annual Cash Flow Conversion Efficiency for Icure Pharmaceutical Incorporation (2015–2024)

The table below shows the annual cash flow conversion efficiency of Icure Pharmaceutical Incorporation from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Icure Pharmaceutical Incorporation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩60.26 Billion ≈ $40.84 Million	₩-17.05 Billion ≈ $-11.56 Million	-0.283x	-24.75%
2023-12-31	₩59.59 Billion ≈ $40.39 Million	₩-13.52 Billion ≈ $-9.16 Million	-0.227x	-80.30%
2022-12-31	₩89.67 Billion ≈ $60.77 Million	₩-11.28 Billion ≈ $-7.65 Million	-0.126x	+54.07%
2021-12-31	₩95.76 Billion ≈ $64.89 Million	₩-26.23 Billion ≈ $-17.77 Million	-0.274x	-147.68%
2020-12-31	₩112.15 Billion ≈ $76.01 Million	₩-12.40 Billion ≈ $-8.41 Million	-0.111x	-81.49%
2019-12-31	₩97.53 Billion ≈ $66.10 Million	₩-5.94 Billion ≈ $-4.03 Million	-0.061x	+29.34%
2018-12-31	₩84.69 Billion ≈ $57.40 Million	₩-7.30 Billion ≈ $-4.95 Million	-0.086x	-234.63%
2017-12-31	₩17.47 Billion ≈ $11.84 Million	₩1.12 Billion ≈ $758.55K	0.064x	+122.24%
2016-12-31	₩16.94 Billion ≈ $11.48 Million	₩-4.88 Billion ≈ $-3.31 Million	-0.288x	-741.49%
2015-12-31	₩5.96 Billion ≈ $4.04 Million	₩-204.05 Million ≈ $-138.28K	-0.034x	--

About Icure Pharmaceutical Incorporation

KQ:175250 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$54.96 Million

₩81.09 Billion KRW

Market Cap Rank

#21528 Global

#1388 in Korea

Share Price

₩2170.00

Change (1 day)

+11.91%

52-Week Range

₩1763.00 - ₩2170.00

All Time High

₩23730.97